Teva Pharmaceutical Industries’ plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.
Earlier on Thursday, two of Israel’s leading financial news websites carried separate reports that Teva, the world’s biggest generic drug maker and Israel’s largest company, planned to fire between 2,000 and 6,000 workers – or as much as 11 percent of the workforce.
A Teva spokesperson had initially declined to comment on the report, but the company later put out a statement saying the figures the media gave were inaccurate.
“The efficiency program is an integral part of Teva’s business reality. The program includes, among other things, ending unprofitable activities and consolidating functions, in addition to freezing recruitment and natural employee turnover,” the company said.
“These processes are conducted through a continuous open dialogue with the employees. This will be the practice, including in Israel, as necessary. We would like to stress that the numbers which were published in the media are incorrect,” it said.
Teva employs around 57,000 people globally.
It has had a rough year, though, with a series of costly acquisitions, along with delayed drug launches, sending its stock plummeting 72 percent to $32.61 the past 12 months.
That forced former chief executive Erez Vigodman to step down in February, with Chairman Yitzhak Peterburg replacing him on a temporary basis.
One of the websites, Calcalist, said Teva has already reduced its workforce in Israel by around 100 people as part of the efficiency plan.
By Ari Rabinovitch and Steven Scheer
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”